RAAV2.5-CMV-minidystrophin (d3990) ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 1 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00428935 (ClinicalTrials.gov) | March 2006 | 26/1/2007 | Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy | Phase 1 Clinical Trial of rAAV2.5-CMV-mini-Dystrophin Gene Vector in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Biological: rAAV2.5-CMV-minidystrophin (d3990) | Nationwide Children's Hospital | Asklepios Biopharmaceutical, Inc. | Completed | 5 Years | 15 Years | Male | 6 | Phase 1 | United States |